Compare Stocks: BBOT, BCAX, RARE, and AVBP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$30.30 -0.1%	$30.12	$17.00 ▼ $35.83	$1.50B	1.35	492,977 shs	1.21 million shs
BBOT BridgeBio Oncology Therapeutics	$4.16 -10.7%	$8.03	$4.05 ▼ $14.87	$333.52M	0.38	654,325 shs	539,620 shs
BCAX Bicara Therapeutics	$20.49 -10.1%	$24.82	$10.48 ▼ $30.99	$1.51B	-0.82	504,105 shs	954,769 shs
RARE Ultragenyx Pharmaceutical	$14.88 -4.7%	$22.84	$12.73 ▼ $39.89	$1.54B	0.31	6.36 million shs	5.70 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-0.07%	+9.58%	+7.22%	-10.43%	+65.85%
BBOT BridgeBio Oncology Therapeutics	-10.73%	-12.61%	-54.49%	-45.90%	+415,999,900.00%
BCAX Bicara Therapeutics	-10.05%	-6.86%	-13.10%	-22.21%	+95.14%
RARE Ultragenyx Pharmaceutical	-4.68%	+15.53%	-42.15%	-49.13%	-47.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$30.30 -0.1%	$30.12	$17.00 ▼ $35.83	$1.50B	1.35	492,977 shs	1.21 million shs
BBOT BridgeBio Oncology Therapeutics	$4.16 -10.7%	$8.03	$4.05 ▼ $14.87	$333.52M	0.38	654,325 shs	539,620 shs
BCAX Bicara Therapeutics	$20.49 -10.1%	$24.82	$10.48 ▼ $30.99	$1.51B	-0.82	504,105 shs	954,769 shs
RARE Ultragenyx Pharmaceutical	$14.88 -4.7%	$22.84	$12.73 ▼ $39.89	$1.54B	0.31	6.36 million shs	5.70 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-0.07%	+9.58%	+7.22%	-10.43%	+65.85%
BBOT BridgeBio Oncology Therapeutics	-10.73%	-12.61%	-54.49%	-45.90%	+415,999,900.00%
BCAX Bicara Therapeutics	-10.05%	-6.86%	-13.10%	-22.21%	+95.14%
RARE Ultragenyx Pharmaceutical	-4.68%	+15.53%	-42.15%	-49.13%	-47.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	2.70	Moderate Buy	$44.86	48.04% Upside
BBOT BridgeBio Oncology Therapeutics	2.80	Moderate Buy	$22.88	449.88% Upside
BCAX Bicara Therapeutics	2.75	Moderate Buy	$32.64	59.28% Upside
RARE Ultragenyx Pharmaceutical	2.48	Hold	$34.58	132.39% Upside

Current Analyst Ratings Breakdown

Latest BBOT, BCAX, RARE, and AVBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	BCAX Bicara Therapeutics	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Equal Weight
9/22/2026	AVBP ArriVent BioPharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	RARE Ultragenyx Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$32.00 ➝ $35.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $20.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $39.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$33.00 ➝ $39.00
9/14/2026	BBOT BridgeBio Oncology Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/11/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$25.00 ➝ $23.00
9/10/2026	BCAX Bicara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	BBOT BridgeBio Oncology Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.44 per share	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$5.14 per share	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.33 per share	N/A
RARE Ultragenyx Pharmaceutical	$673M	2.18	N/A	N/A	($0.83) per share	-17.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$166.31M	-$3.62	N/A	N/A	N/A	N/A	-50.26%	-46.66%	11/16/2026 (Estimated)
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.76	N/A	N/A	N/A	N/A	-46.90%	-42.17%	N/A
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)

Latest BBOT, BCAX, RARE, and AVBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	AVBP ArriVent BioPharma	-$0.9873	-$1.05	-$0.0627	-$1.05	N/A	N/A
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.16	14.16
BBOT BridgeBio Oncology Therapeutics	N/A	4.69	4.69
BCAX Bicara Therapeutics	N/A	11.59	11.59
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
BBOT BridgeBio Oncology Therapeutics	54.89%
BCAX Bicara Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	8.58%
BBOT BridgeBio Oncology Therapeutics	24.40%
BCAX Bicara Therapeutics	13.80%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	77	49.31 million	45.08 million	N/A
BBOT BridgeBio Oncology Therapeutics	88	80.17 million	60.61 million	N/A
BCAX Bicara Therapeutics	103	66.17 million	57.04 million	N/A
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

BBOT, BCAX, RARE, and AVBP Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

September 22 at 8:17 PM | globenewswire.com

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

September 22 at 3:43 PM | finance.yahoo.com

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

September 22 at 7:10 AM | insidermonkey.com

Bank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RARE

September 22 at 3:04 AM | marketbeat.com

Ultragenyx Pharmaceutical stock gains after FDA approval and fresh analyst targets

September 21 at 12:49 PM | ad-hoc-news.deA

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $35.00 Price Target at Barclays

September 21 at 9:00 AM | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Barclays Analyst Says

September 21 at 8:59 AM | marketbeat.com

Comparing Anixa Biosciences (NASDAQ:ANIX) and Ultragenyx Pharmaceutical (NASDAQ:RARE)

September 21 at 8:00 AM | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

September 20, 2026 | americanbankingnews.com

Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

September 20, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Citigroup Analyst Says

September 20, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Strong Trading Volume Following Analyst Upgrade

September 20, 2026 | americanbankingnews.com

Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

September 19, 2026 | theglobeandmail.com

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity

September 19, 2026 | theglobeandmail.com

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

September 19, 2026 | finance.yahoo.com

Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVI™ to Treat ...

September 18, 2026 | newswise.comN

Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo

September 18, 2026 | medcitynews.comM

Ultragenyx sets $3.95m list price for fatal rare disease therapy

September 18, 2026 | emjreviews.comE

Ultragenyx Pharmaceutical stock jumps on Fayuvi FDA approval and fresh Cantor Fitzgerald target

September 18, 2026 | ad-hoc-news.deA

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says

September 18, 2026 | marketbeat.com

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

September 18, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BBOT, BCAX, RARE, and AVBP Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$30.30 -0.02 (-0.07%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$30.28 -0.03 (-0.08%)

As of 08:19 AM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$4.16 -0.50 (-10.73%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.30 +0.14 (+3.37%)

As of 08:36 AM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Bicara Therapeutics NASDAQ:BCAX

$20.49 -2.29 (-10.05%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$20.48 0.00 (-0.02%)

As of 08:45 AM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.88 -0.73 (-4.68%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$14.75 -0.13 (-0.87%)

As of 09:14 AM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBOT, BCAX, RARE, and AVBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBOT, BCAX, RARE, and AVBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBOT, BCAX, RARE, and AVBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BBOT, BCAX, RARE, and AVBP Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Bicara Therapeutics NASDAQ:BCAX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBOT, BCAX, RARE, and AVBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBOT, BCAX, RARE, and AVBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBOT, BCAX, RARE, and AVBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BBOT, BCAX, RARE, and AVBP Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Bicara Therapeutics NASDAQ:BCAX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools